Compugen Ltd. - (CGEN) closed at $2.04 on October 29, 2026, up 1.5% from the previous close, on volume of 141,725 shares (30-day average 204,632).
Data as of October 29, 2026.
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
PRNewswire (Mon, 26-Oct 7:00 AM ET)
PRNewswire (Tue, 6-Oct 7:00 AM ET)
PRNewswire (Tue, 22-Sep 7:00 AM ET)
PRNewswire (Tue, 8-Sep 7:00 AM ET)
Compugen Reports Second Quarter 2026 Results
PRNewswire (Mon, 3-Aug 7:00 AM ET)
Solid Cash Position and Advancing Clinical Trials Define Compugen’s Q1 2026 Results
Market Chameleon (Mon, 18-May 7:45 AM ET)
Market Chameleon (Mon, 2-Mar 6:15 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of October 30, 2026, CGEN stock price declined to $1.99 with 73,727 million shares trading.
CGEN has a beta of 1.56, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.10 to the broad based SPY ETF.
CGEN has a market cap of $186.09 million. This is considered a Micro Cap stock.
Last quarter Compugen Ltd. - reported $3 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.
In the last 3 years, CGEN traded as high as $3.24 and as low as $.53.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, AVDV, GWX, QQQS, AVSD.
CGEN has outperformed the market in the last year with a return of +20.6%, while the SPY ETF gained +11.0%. However, in the most recent history, CGEN shares have underperformed the stock market with its stock returning -11.2% in the last 3 month period and -4.3% for the last 2 week period, while SPY has returned +3.8% and -2.1%, respectively.
CGEN support price is $1.96 and resistance is $2.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN shares will trade within this expected range on the day.
